Tirzepatide (Zepbound / Mounjaro)

Tirzepatide is a dual agonist — it activates both GLP-1 and GIP receptors. This produces greater weight loss than semaglutide on average (18–22% vs 12–15% across head-to-head data) and slightly stronger glycemic control. It's the active ingredient in Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for weight loss). At Elements, our tirzepatide programs include the medication, structured lifestyle support, and ongoing labs.

Tirzepatide protocols at Elements follow the same structured framework as semaglutide: initial consultation, baseline labs, dose titration starting at 2.5mg weekly and progressing to maintenance over 16–20 weeks. We pair medication with protein targets (typically 0.8–1g per pound goal body weight) and resistance training prescription to preserve lean mass. Side effects mirror semaglutide but tend to be slightly more pronounced during early titration — GI symptoms peak in weeks 1–2 of each dose increase. Less common: pancreatitis (rare), gallbladder issues. Contraindications match semaglutide. Pricing: brand-name (Zepbound) typically runs $1,000–$1,300/month without insurance, often covered with diabetes diagnosis; compounded tirzepatide where available runs $400–$700/month. We stay current on FDA compounding guidance and adjust supply accordingly.

Key Benefits